23andMe Moving into Clinical Trial Recruitment, a Potential Source of New Income

I have been blogging about23andMe for about six years (see:Update on 23andMe; Time for a Review of FDA Definition of Medical Devices). During that time, I have seen the company evolve from the first major consumer genomics enterprise to a clinical laboratory authorized by the FDA to perform testing for ten diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information about an individual ’s genetic predisposition to certain medical diseases or conditions (see:FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions). Previous reporting about the company indicates that it is also seeking to become a drug company with 13 drug candidates in its pipeline (see:23andMe wants to become a drug company, has 13 drugs in its pipeline: 5 notes). Now comes news that it is aggressively pursuing a new goal -- clinical trial recruitments (see:23andMe, moving beyond consumer DNA tests, is building a clinical trial recruitment business). Below is an excerpt from this latest article: Consumer genetics giant 23andMe announced....that it would move deeper into the business of clinical trial recruitment, partnering with a fast-growing startup to help match its customers with nearby study sites based on their diseases, demographics, and DNA. The Silicon Valley company has for months been quietly making inroads into clinical trial recruitment by emailing customers...
Source: Lab Soft News - Category: Laboratory Medicine Authors: Tags: Food and Drug Administration Genomic Testing Healthcare Information Technology Healthcare Innovations Lab Industry Trends Lab Regulation Lab Standards Medical Consumerism Medical Research Pharmaceutical Industry Source Type: blogs